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OBJECTIVES The objective of this study was to determine the prognostic value of C-reactive protein (CRP)
independent of coronary angiographic findings.
BACKGROUND High sensitivity CRP, a marker of inflammation, predicts risk of cardiovascular events.
However, it is uncertain whether it remains predictive once angiographic findings are
considered.
METHODS A total of 2,554 patients with angina but without acute myocardial infarction (MI) were
studied angiographically; 1,848 patients had coronary artery disease (CAD) and 706 patients
did not. Coronary artery disease was quantified in five ways and combined for a CAD score.
C-reactive protein was measured and patients were followed for up to five years for death or
MI.
RESULTS C-reactive protein correlated with the extent of CAD, but correlation coefficients were low
(0.02 to 0.08). Of angiographic measures, the CAD score best predicted future events (hazard
ratio [HR] 1.8 [1.2 to 2.6], p 0.004, for CAD score4). C-reactive protein1.0 mg/dl
was predictive in both patients without CAD (HR  2.3 [0.9 to 5.5], p  0.07) and with
CAD (HR  2.1 [1.5 to 3.1], p  0.0001). Multivariate adjustment resulted in little change
in HR. C-reactive protein retained predictive value within each quintile of CAD score.
C-reactive protein and CAD independently and additively contributed to the risk prediction:
low CRP and lowest CAD score was associated with lowest risk, and high CRP and highest
CAD score was associated with the highest risk, with a 10-fold difference between extremes
(2.5% vs. 24%).
CONCLUSIONS C-reactive protein correlates with extent of CAD, but the degree of correlation is low.
Severity/extent of CAD and CRP are independent and additive predictors of risk. Therapy
should target CRP-associated risk as well as angiographically evident stenosis. (J Am Coll
Cardiol 2002;39:632–7) © 2002 by the American College of Cardiology
High sensitivity C-reactive protein (CRP), a marker of
systemic inflammation, has been evaluated as a risk predic-
tor in subjects without known coronary artery disease
(CAD) (1,2), in those at risk of CAD (3,4) and in patients
with stable angina (5), unstable angina (6–11) or acute
myocardial infarction (MI) (12). Even small elevations of
CRP, within or just beyond the “normal” range (determined
by high sensitivity CRP assay) have been found to strongly
predict future cardiovascular events in almost all studies.
However, these studies have not adjusted for plaque burden
as assessed by coronary angiography (1–11). When adjust-
ments for CAD have been made, they generally have been
limited to adjustment for one-, two- or three-vessel disease
(12). In our own prior report, we limited analysis to those
with angiographically severe CAD (13). In primary risk
studies, angiographic information to allow for any adjust-
ment is generally unavailable. Thus, it is possible that
elevated CRP may simply be a surrogate of atherosclerosis
burden. Some previous studies have shown a correlation
between CRP and the presence of atherosclerosis (14),
whereas others have not found a correlation (15). C-reactive
protein might lose much if not all of its predictive value in
both secondary and primary risk settings after adjustment
for quantitative angiographic measures of CAD. On the
other hand, CRP might add independently to measures of
CAD extent and severity.
METHODS
Study objectives. Our principal study objectives were to
determine: 1) whether CRP correlates with the extent of
CAD as assessed by various angiographic findings; 2)
whether CRP remains an independent predictor of death or
MI after adjustment for various angiographic findings; 3)
whether the predictive value of CRP differs among subjects
with a normal angiogram and those with mild, moderate or
extensive CAD; and 4) the risk of death or MI among
subgroups of CRP and CAD severity.
Patients and follow-up. The study sample included con-
secutive consenting patients undergoing coronary angiogra-
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phy at a single hospital between 1994 and 1997 for
evaluation of symptoms suggestive of stable or unstable
angina. Patients with acute MI (whose CRP levels are
affected by an acute-phase reaction) were excluded. Creatine
kinase-MB, if drawn before angiography, was uniformly
normal. This series was enrolled before widespread testing
with troponin assays. Most subjects were residents of Utah,
southwestern Idaho or southeastern Wyoming, a population
genetically representative of U.S. Caucasians (16). The
study was approved by the hospital’s institutional review
board.
Clinical events during follow-up were determined
through telephone calls and hospital records, with supple-
mental information from a national death registry enabling
100% determination of vital status.
Determination of CAD severity. All angiograms were
reviewed by an attending cardiologist blind to CRP level
and future outcome, and each lesion was visually estimated
for percent diameter stenosis rounded to the nearest 10%.
The presence of a mild/moderate (10% to 60%) or a severe
lesion (70% to 100%) in the left anterior descending, the
circumflex or the right coronary artery defined the vessel as
a mild/moderately or severely affected vessel (or both).
The extent of CAD was quantified in six ways: 1) the
number of distinct lesions with 10% to 60% stenosis (range
0 to 18); 2) the number of distinct lesions with 70%
stenosis (range 0 to 15); 3) the total number of lesions
(range 0 to 22); 4) the number of vessels with 10% to 60%
stenosis (range 0 to 3); 5) the number of vessels with 70%
stenosis (range 0 to 3); and 6) a CAD score (the total
number of lesions plus the number of vessels with at least
one severe lesion plus the number of vessels with at least one
moderate lesion [range 0 to 28]). We chose a priori to
evaluate each measured angiographic finding individually
and cumulatively in a CAD score and determine the
strongest CAD predictor of future events.
Determination of CRP. C-reactive protein was quantified
by a fluorescence polarization immunoassay (Abbott Diag-
nostics, Abbott Park, Illinois). All plasma was analyzed by
the high sensitivity (0.05 mg/dl threshold) protocol, with a
range of results of 0.05 to 6.5 mg/dl. All samples with
a CRP exceeding 6.5 mg/dl were reanalyzed by a lower
sensitivity (1.5 mg/dl) protocol, with a range of results of
up to 26 mg/dl. The test is standardized to the International
Federation of Clinical Chemistry International Reference
Preparation for Plasma Proteins. The within-run coefficient
of variation for a 1.78-mg/dl standard is 3.7%. Between-run
coefficients of variation are 3.9% for a 0.74-mg/dl standard
and 3.0% for a 9.08-mg/dl standard.
We chose a priori to define an elevated CRP as 1.0
mg/dl, a commonly used cutpoint to define high risk in the
literature and our previous studies in CAD populations; this
level exceeds the 98th percentile for clinically normal indi-
viduals (Abbott Laboratories). We also chose to define a
highly elevated CRP level as2.0 mg/dl, approximately the
top CRP quintile.
Statistical considerations. Baseline demographic and lab-
oratory information is presented as mean (standard devia-
tion) for continuous variables and frequencies for discrete
variables. Comparisons among groups used analysis of
variance for continuous variables and chi-square testing for
discrete variables. Survival statistics were used for risk
determinations. The primary outcome variable was the
combination of death (all-cause) and nonfatal MI. Only the
first event was counted as an end point. Secondary outcome
variables were nonfatal MI alone. Cox regression analysis
was used for assessment of the relative hazard of these
events over time. Both univariate and multivariate analyses
were performed using SPSS for Windows, version 9.0.1
(SPSS Inc., Chicago, Illinois). Cox multivariate adjust-
ments of hazard ratios used a forced-entry approach, and
multivariate modeling used a backward conditional stepwise
regression approach.
Traditional risk factors used in multivariable analyses
included age, gender, diabetes, smoking history (current or
10 pack years), family history of CAD, diagnosis of
hypertension, diagnosis of hyperlipidemia and type of treat-
ment after angiography (medical, angioplasty or surgery).
Complete data on these risk factors were available in 2,487
of the subjects. Baseline demographic information on lipid
levels, ejection fraction and blood pressure were available in
965, 2,152 and 2,472 subjects, respectively.
RESULTS
Subject population and demographics. A total of 2,554
subjects were enrolled who had angiographic and baseline
demographic information and a baseline CRP level.
Subjects were followed to up to five years (mean 2.1 
1.2 years). Patients presenting with symptoms consistent
with stable angina comprised 65% of the study cohort; an
unstable angina presentation made up the other 35%.
Among the entire group, angioplasty was performed in 9%,
bypass surgery in 19% and medical therapy only was given to
72%. Discharge rates of medications were 55% for aspirin,
35% for angiotensin-converting enzyme (ACE) inhibitors,
16% for beta-blockers and 12% for statins.
Baseline demographics are presented by CAD category in
Table 1. Subjects were divided into “quintiles” that included
those with a normal angiogram (n  706) and those in
CAD score quartiles representing mild (n  424, score 1
to 4), moderate (n  537, score 5 to 8), moderately severe
(n  439, score 9 to 11) and severe CAD (n  448, score
Abbreviations and Acronyms
ACE  angiontensin-converting enzyme
CAD  coronary artery disease
CI  confidence interval
CRP  C-reactive protein
HR  hazard ratio
MI  myocardial infarction
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12). As the severity of CAD increased, each traditional
risk factor increased in prevalence or severity (p  0.05 for
all except diastolic blood pressure and total cholesterol).
Median CRP values were higher in patients with CAD than
without CAD (1.15 vs. 1.23 mg/dl, p  0.001), and CRP
increased with increasing CAD severity (p  0.001, Table 1).
Correlations of CRP with CAD severity/extent. C-
reactive protein correlated with the severity/extent of CAD
for the entire cohort by all measures of CAD (p  0.008)
except for the number of moderate lesions; however, corre-
lation coefficients were very low (0.02 to 0.08) (Table 2).
Among all measures of CAD, the strongest correlation with
CRP was with the CAD score, which was used in further
analyses.
Predictive value of CAD score. In the CAD group, there
were 248 events of death or nonfatal MI during follow-up,
with 221 of these counting as the first event. The CAD
score predicted future events with a hazard ratio (HR) of
1.08 per unit increase in score (95% confidence interval [CI]
1.04 to 1.11, p  0.0001) or a HR of 1.8 (CI 1.2 to 2.6,
p  0.004) for a CAD score 4 (vs. 4). After adjustment
for CRP, the HR was unchanged. After adjustment for
CRP and traditional risk factors, the CAD HR also was
undiminished: 1.09 per unit increase in score (CI 1.05 to
1.13, p  0.0001) or 1.8 (1.2 to 2.6, p  0.005) for a CAD
score 4.
Predictive value of CRP for future events. In the overall
study group, CRP 1.0 mg/dl predicted subsequent
death/MI with an unadjusted HR of 2.3 (CI 1.6 to 3.2, p
0.0001). In the large CAD subgroup (n  1,848), CRP
1.0 mg/dl predicted events with an unadjusted HR of 2.1
(CI 1.5 to 3.1, p  0.0001). Adjustment for CAD severity
and traditional risk factors resulted in little change in the
predictive value of CRP (Table 3), with a fully adjusted HR
of 1.9 (CI 1.3 to 2.8, p 0.002). In the subgroup of patients
with normal angiograms (n  706), there were 32 events of
death or MI during follow-up, with 27 counting as a first
event. C-reactive protein1.0 mg/dl predicted an increased
relative hazard for death or MI similar to that found in the
CAD group (HR  2.3 [CI 0.9 to 5.5], p  0.07).
Joint predictive value of CRP and CAD score for death
or MI. The entire group also was evaluated for the absolute
risk of death or MI among quintiles of CAD score and low
(1.0 mg/dl; 28% of patients with CAD), moderate (1.0 to
2.0 mg/dl; 55%) or high (2.0 mg/dl; 17%) levels of CRP.
Increasing CRP and increasing CAD independently and
additively contributed to the risk prediction for death or MI
such that a low CRP and the lowest CAD score was
associated with the lowest risk, and high CRP and the
highest CAD score was associated with the highest risk
(Fig. 1). A 10-fold difference was observed between these
extremes (2.5% vs. 24% risk). Importantly, CRP retained its
predictive value within each subgroup of CAD score, and
CAD score retained its predictive value within each sub-
group of CRP. Indeed, the absolute risk for death or MI
among patients with lowest CAD scores and highest CRP
levels was nominally greater than the risk for patients with
highest CAD scores and lowest CRP levels. This occurred
despite higher levels of standard risk factors in the group
with more extensive CAD (Table 1).
Table 1. Baseline Demographics
CAD score
0
(n  706)
1 to 4
(n  424)
5 to 8
(n  537)
9 to 11
(n  439)
12 to 28
(n  448)
p Value for
Trend
Age, years 59 63 65 67 67  0.001
Men 50% 63% 72% 79% 81%  0.001
Hypertension 45% 51% 56% 59% 63%  0.001
Hyperlipidemia 28% 43% 52% 56% 65%  0.001
Diabetes 10% 12% 14% 19% 23%  0.001
Family history of CAD 29% 30% 33% 35% 35% 0.007
Tobacco use (current or 10 pack-years) 17% 23% 24% 24% 21% 0.018
Ejection fraction 65% 66% 62% 61% 59%  0.001
Blood pressure, mm Hg 142/80 145/80 146/81 147/79 147/79 0.009/NS
Cholesterol/HDL, mg/dl 176/38 183/34 180/33 184/34 180/32 NS/0.004
CRP, median, mg/dl 1.15 1.18 1.21 1.23 1.28  0.001
Days of follow-up, mean 705 756 764 789 736 NS
Death or nonfatal MI 5.0% 7.3% 9.5% 16.2% 18.3%  0.001
CAD  coronary artery disease; CRP  C-reactive protein; HDL  high-density lipoprotein; MI  myocardial infarction; NS  nonsignificant, p  0.05.
Table 2. Correlation Coefficients for CRP and Angiographic
Measures of CAD
Angiographic
Marker
All Subjects
(n  2,598)
CAD Present
(n  1,904)
Pearson’s p Value Pearson’s p Value
# of moderate lesions 0.02 0.25 0.02 0.46
# of severe lesions 0.05 0.007 0.06 0.12
# of total lesions 0.05 0.008 0.06 0.01
# of moderate vessels 0.07 0.001 0.06 0.012
# of severe vessels 0.08 0.001 0.06 0.013
CAD score 0.08 0.001 0.06 0.006
Severe lesion is defined as 70% stenosis; moderate lesion is defined as 10%–60%
stenosis; severe vessel is a coronary artery with at least one severe lesion (maximum 3);
moderate vessel is a coronary artery with at least one moderate lesion (maximum 3).
CAD score is defined as the # of total lesions plus # of severe and moderate vessels
(range 0 to 28).
CAD  coronary artery disease; CRP  C-reactive protein.
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CRP, CAD score and risk of MI. The risk of MI alone
(n  100) also increased with increasing CRP levels and
with increasing CAD score. The absolute incidence of MI
among patients with a normal angiogram was only 0.4%
with CRP 1.0 mg/dl and 0.3% for CRP 1.0 to 2.0 mg/dl,
but it was 4.0% for CRP 2 mg/dl (p  0.0003). The
incidence of MI also increased with higher CRP group
(from 1.6% to 4% to 7.1%, respectively) among those with
mild CAD (score 1 to 4). Among those with moderate
CAD (score 5 to 8), the incidence of MI also increased with
increasing CRP category (from 1.4% to 4.4% to 5.1%,
respectively). Similarly among those with moderately severe
CAD (score 9 to 11), the incidence of MI increased with
increasing CRP category (from 5.9% to 4.7% to 9.2%,
respectively). Finally, among patients with extensive CAD
(score 12 to 28), rates of MI were 6.4%, 5.8% and 7.4%,
respectively, by CRP category.
DISCUSSION
Study summary and perspective. In this study, we have
shown that although CRP significantly correlates with the
extent of vascular disease, the degree of association is small
and the independent contribution of CRP to risk assess-
ment remains very large. Because CRP is weakly correlated
with angiographic plaque burden, it appears that CRP is
stimulated not only by the extent of atherosclerosis but,
importantly, by other factors. We postulate that CRP is a
measure of inflamed, unstable atherosclerotic plaque (both
angiographically visible and occult), whereas angiography
indicates the extent of visible stable and unstable occlusive
Table 3. Hazard Ratio of Elevated CRP for Death or Nonfatal Myocardial Infarction Among
Subjects With Angiographic Adjusted for Various Angiographic Markers* on Disease Severity
Adjusted for
Hazard Ratio for
CRP >1.0 mg/dl 95% CI p Value n
Unadjusted 2.1 1.5–3.1 0.0001 1,904
# of moderate lesions 2.1 1.5–3.1 0.0001
# of moderate vessels 2.0 1.4–3.0 0.0002
# of severe lesions 2.0 1.4–2.9 0.0002
# of severe vessels 2.0 1.4–2.9 0.0003
# of total lesions 1.9 1.3–2.8 0.0007
CAD score† 1.9 1.3–2.8 0.0009
CAD score and traditional risk factors‡ 1.9 1.3–2.8 0.0018 1,772
*Severe lesion is defined as70% stenosis; moderate lesion is defined as 10%–60% stenosis; severe vessel is a coronary artery with
at least one severe lesion (maximum 3); moderate vessel is a coronary artery with at least one moderate lesion (maximum 3).
†Score defined as the # of total lesions plus # of severe and moderate vessels (range 0–28). ‡Traditional risk factors include age,
gender, hypertension, diabetes, hyperlipidemia, family history, smoking history and treatment modality after angiography
(medical, angioplasty or surgery).
CAD  coronary artery disease; CI  confidence interval; CRP  C-reactive protein.
Figure 1. Cumulative incidence of all-cause mortality or myocardial infarction (MI) during follow-up by coronary artery disease (CAD) score and
C-reactive protein (CRP). Among 2,554 patients presenting with stable or unstable angina, the extent of CAD was defined as a CAD score (total number
of lesions  total number of moderate and severe coronary vessels). A CAD score of 0 equals a normal angiogram. Subjects with a positive score were
divided into quartiles. C-reactive protein was defined as low (1 mg/dl, 28% of patients), moderately elevated (1.0 to 2.0 mg/dl, 55% of patients) or highly
elevated (2 mg/dl, 17% of patients). The percent of each group with death or MI during follow-up is noted on each column.
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plaque. C-reactive protein also may reflect systemic but
nonvascular chronic inflammatory and infectious processes
that impact risk of acute coronary events by influencing
levels of circulating proinflammatory and prothrombotic
factors.
Whatever the explanation, our study clearly shows that
CRP and angiographic CAD are largely independent fac-
tors in determining risk. The value of CRP in predicting
future death or MI is apparent in all ranges of CAD
severity. Those with extensive CAD are at relatively high
risk of death or MI regardless of CRP levels. However, in
the presence of a low to moderate risk angiogram (or even
a normal angiogram), CRP becomes particularly useful in
distinguishing patients at substantially lower versus higher
risk for death or MI. A particularly high risk is observed in
subjects with lower CAD scores but highly elevated CRP
despite a lower prevalence of all traditional risk factors in
these patients with low/moderate CAD scores (i.e., lower
cholesterol levels, absence of diabetes, hypertension, etc.).
Because these patients may be considered to have “insignif-
icant CAD” and hence to be at low risk for MI, less
aggressive medical therapy may be offered to them in
comparison to patients with more extensive CAD.
Historical perspective. Several trials have evaluated the
predictive value of CRP for cardiovascular risk. However,
much remains to be learned to explain CRP’s association
with risk. Levels of CRP that define increased risk vary
depending on the population studied. The degree of eleva-
tion of CRP that identifies increased risk has not been
clearly determined, and the clinical utility of CRP after
adjustment for angiographic findings has been uncertain.
C-reactive protein previously has been proposed to correlate
with the extent of atherosclerosis (14). Studies have shown
that lower profile plaques are more numerous than “signif-
icant stenoses” and, therefore, are statistically more likely to
lead to plaque rupture than the relatively few lesions of
70% stenosis (17). Thus, it is possible that an elevated
CRP simply represents a more diffuse process of coronary
atherosclerosis with a higher total plaque burden. If so, the
predictive value of CRP would be considerably less after
adjustment for extent of disease (total number of lesions)
assessed by coronary angiography. To exclude this possibil-
ity, the predictive value of CRP must be adjusted for
measures of all visible atherosclerotic plaques on angiogra-
phy. On the other hand, if CRP levels primarily represent
plaque properties (i.e., inflammation, instability), knowl-
edge of CRP levels would continue to be useful even in the
presence of angiographic assessment of plaque burden
(extent/severity). Similarly, CRP and coronary calcium
score (assessed by ultrafast computed tomography) may
have independent and additive prognostic value, but this has
not been extensively evaluated.
Therapeutic implications. Previous studies have shown
that aspirin (1) and statin therapy (18,19) are more effective
in subjects with elevated CRP. Other therapies that reduce
risk of MI or cardiovascular death (i.e., ACE inhibitors,
beta-blockers, diet, exercise, etc.) also may be especially
beneficial and cost-effective in these patients at higher than
expected risk for cardiovascular events and deserve further
evaluation. Thus, CRP may be useful both in determining
risk category and in guiding therapy, not only in those
without angiographic evaluation but even in the presence of
quantitative assessments of anatomic CAD. In our patients,
the rates of discharge medications in those with more severe
disease were greater than in those with no or moderate
disease. However, prescription rates remain suboptimal even
when patients without CAD were excluded from analysis.
Similarly, in recent national reports, discharge prescriptions
for aspirin, statins, beta-blockers and ACE inhibitors re-
main suboptimal (20,21). Elevation of CRP may give
physicians additional information prompting the use of
optimal medical therapies. In our experience, discharge of
patients undergoing angiographic assessment on a statin was
associated with improved long-term compliance and re-
duced mortality (18,22).
Study limitations. The limitations of this study are those
inherent to all prospective but nonrandomized registries.
Quantification of coronary angiographic findings was lim-
ited to the visual interpretation of the attending cardiologist,
which is representative of “real-world” practice. Intravascu-
lar ultrasound could be expected to give increased measures
of atherosclerotic burden by identifying “intramural
plaques,” although this would be impractical to apply
routinely. However, whether intravascular ultrasound as-
sessments would adversely impact predictive value of CRP is
unclear. The cause of death was available in fewer than half
of cases, so our analyses relied on total rather than cause-
specific (cardiovascular) death. However, among patients in
whom cause of death could be determined, 75% were
cardiovascular, and trends seen in overall event rates also
were found for documented cardiovascular events alone (not
shown). Use of total mortality also would tend to underes-
timate the predictive value of CRP for cardiovascular events.
The use of medical therapy for CAD likely is more extensive
in patients with more advanced angiographic CAD. If so,
CRP has utility in identifying patients with less extensive
CAD who are at equally high risk and who may also benefit
from aggressive medical therapy. Only patients with clinical
presentations suggesting stable or unstable angina who
underwent angiography were included in our study. How-
ever, the vast majority of patients undergoing angiography
today do so for evaluation of suspected angina. Many of
these patients (about 20%) have normal angiograms. It often
is difficult to determine which of these patients have true
angina related to occult microvascular disease or endothelial
dysfunction and which truly have noncardiac chest discom-
fort. C-reactive protein thus appears to be useful in evalu-
ating risk in patients without visible CAD, although the
beneficial effects of more aggressive medical therapy in these
patients (18,22) should be further evaluated.
Conclusions. In a large prospectively and angiographically
studied population, CRP correlated significantly with sev-
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eral measures of the extent and severity of CAD, but the
degree of correlation was low, suggesting that other factors
are more important in determining CRP levels. When
studied jointly, the extent of CAD and CRP levels retain
independent predictive value for death or MI, and adjust-
ment in multivariate analysis does not significantly alter the
predictive value of either CRP or CAD score.
We postulate that CRP identifies primarily properties of
plaque (i.e. inflammation, instability), whereas CAD score
identifies extent of atherosclerotic plaque. Perhaps surpris-
ingly, these two measures of atherosclerotic disease are
largely independent of each other and confer additive risk.
Patients presenting with chest pain who have a low or
intermediate risk angiogram and high CRP levels (1.0 to
2.0 mg/dl) are at relatively high risk and may warrant
particularly aggressive risk factor reduction, medical therapy
and close follow-up.
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